Intellectual Property

Immuron has a policy to identify, capture and protect all relevant intellectual property associated within its core business strategies. The company has a long history of decisively managing its intellectual property, using in-house IP specialists and external patent and trademark attorney firms located both globally and within Australia.

Immuron manages four separate families of patent cases, requiring prosecution in each of the major global jurisdictions. All such cases are in different stages of development and prosecution. The company further maintains a significant register of trademarks, particularly in association with the product Travelan.

Due to the practical nature of the technology used to produce Travelan, the company also retains a significant amount of know-how and other unregistered intellectual property which presents significant hurdles to competitors in producing the same products. In its relationships with Hadasit and the Monash University, the company continues its policy of actively in-licensing and filing upon new technology that relates to all relevant business objectives. 

Immuron currently has a suite of 30 patents either approved or pending that cover the full spectrum of its Technology Platform.

 

Travelan ETEC: Composition and Method for the Treatment and Prevention of Enteric Bacterial Infections

Number

Country

Status

Expiry

2004216920

Australia

Granted

4 March 2024

0408085-8

Brazil

Pending

4 March 2024

2,517,911

Canada

Granted

4 March 2024

201210055406.0

China

Pending

4 March 2024

04716992.5

Europe

Pending

4 March 2024

230,664

India

Granted

4 March 2024

542088

New Zealand

Granted

4 March 2024

10/548,156

USA

Granted

4 March 2024

14/138,834

USA

Pending

4 March 2024

 

‘LPS1’ Anti LPS Enriched Immunoglobulin Preparation For Use In Treatment and/or Prophylaxis Of A Pathologic Disorder

Number

Country

Status

Expiry

2010243205

Australia

Granted

27 April 2030

PI1014774-8

Brazil

pending

27 April 2030

2760096

Canada

pending

27 April 2030

201171304

Eurasia

Issued

27 April 2030

13/265,252

USA

Published

27 April 2030

10721856.2

Europe

Published

27 April 2030

12103554.8

Hong Kong

Published

27 April 2030

315924

Israel

Allowed

27 April 2030

2012-507877

Japan

Granted

27 April 2030

10-2011-7027634

South Korea

Issued

27 April 2030

MX/a/2011/011376

Mexico

Published

27 April 2030

 

‘LPS2’ Anti LPS Enriched Immunoglobulin Preparation For Use In Treatment and/or Prophylaxis of a Pathologic Disorder

Number

Country

Status

Expiry

2011290478

Australia

Granted

27 April 2030

2808361

Canada

Pending

27 April 2030

11793860.5

Europe

Validated

27 April 2030

9,943,597

USA

Issued

27 April 2030

 

IMM 529 Methods and Compositions for the Treatment and/or Prophylaxis of Clostridium Difficile Associated Disease

Number

Country

Status

Expiry

2014253685

Australia

Pending

19 April 2034

2,909,636

Canada

Pending

19 April 2034

2986316

Europe

Pending

19 April 2034

14/785,527

USA

Pending

19 April 2034

201480034857.3

China

Pending

19 April 2034

713233

NZ

Pending

19 April 2034